Healthcare Equipment and Supplies
Company Overview of CardioDx, Inc.
CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.
600 Saginaw Drive
Redwood City, CA 94063
Founded in 2003
Key Executives for CardioDx, Inc.
Founder, Chief Executive Officer, President and Director
Senior Vice President of Human Resources
Vice President of Development
Compensation as of Fiscal Year 2015.
CardioDx, Inc. Key Developments
CardioDx Appoints Timothy Henn as Chief Financial Officer
Dec 27 15
CardioDx has appointed Timothy Henn as Chief Financial Officer of the company. The company noted yjay Henn is a seasoned executive in the healthcare industry, including experience with both private and public companies. Prior to joining CardioDx, he served as Chief Financial Officer of Crescendo Biosciences.
CardioDx, Inc. and Quest Diagnostics Sign Agreement to Expand Patient Access to the Corus Cad Test
Sep 16 15
CardioDx, Inc. announced a national specimen-draw agreement with Quest Diagnostics that will expand patient and clinician access to the Corus CAD lab-developed blood test for aiding the assessment of obstructive coronary artery disease (CAD). Under a multi-year agreement, clinicians will be able to order blood draws on patients for testing through Quest's approximately 2,200 patient service centers and 4,000 phlebotomists in physician offices in the United States. Samples will be forwarded to CardioDx's CLIA-certified laboratory (in Redwood City, Calif.) for testing.
CardioDx, Inc. Announces Positive Results from Clinical Utility Study
Apr 1 15
CardioDx, Inc. announced the publication of a new study examining the effect of the use of an age, sex, and gene expression score on clinical decision-making and the rate of further cardiac evaluation in symptomatic female patients in the outpatient setting. The study examined the use of the Corus CAD test, a blood test which incorporates age, sex, and gene expression, in 320 women presenting with stable symptoms suggestive of obstructive coronary artery disease (CAD). The study indicated that women with low Corus CAD test scores (=15) were significantly less likely to be referred for further cardiac evaluation (OR 0.013, p<0.0001) by their primary care clinicians within 45 days of follow-up. Only 4% of women (10/248) with low Corus CAD test scores received further testing for obstructive CAD. The Corus CAD test is the first and only commercially available blood-based test incorporating age, sex, and gene expression measurements that provides a current-state assessment of obstructive CAD in non- diabetic patients presenting with non-acute typical or atypical symptoms. The study included 320 women presenting to 16 primary care providers across 9 practice sites and 6 states. The mean Corus CAD test score was 10.3±8.2, with a range of 1 (corresponding to a 1% likelihood of obstructive CAD) to 38 (corresponding to a 62% likelihood of obstructive CAD). Overall, 77.5% of women (248/320) had low Corus CAD test scores. The referral rate for further cardiac evaluation was 4% (10/248) among women with low Corus CAD test scores versus 83.3% (60/72) among women with elevated scores (p<0.0001).
Similar Private Companies By Industry
Recent Private Companies Transactions
September 16, 2015
June 25, 2015